Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.
Months after cancer drug trial, Merus agrees to be bought at 41% premium
Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.
